5439-17-8

Basic information

• Product Name: 2-BROMO-N-(3-METHYLPHENYL)ACETAMIDE
• Synonyms: AKOS BB/0105;2-BROMO-N-(3-METHYLPHENYL)ACETAMIDE;2-BROMO-N-M-TOLYL-ACETAMIDE;CHEMBRDG-BB 4023662;AKOS BBB/457;acetamide, 2-bromo-N-(3-methylphenyl)-;2-bromo-N-(3-methylphenyl)ethanamide;2-bromo-N-(3-methylphenyl)acetamide(SALTDATA: FREE)
• CAS NO: 5439-17-8
• Molecular Formula: C₉H₁₀BrNO
• Molecular Weight: 228.09
• Mol File: 5439-17-8.mol
• Article Data: 25

Chemical Properties

• Boiling Point: 351.5 °C at 760 mmHg
• Flash Point: 166.4 °C
• Appearance: /
• Density: 1.5 g/cm³
• Vapor Pressure: 4.08E-05mmHg at 25°C
• Refractive Index: 1.615
• CAS DataBase Reference: 2-BROMO-N-(3-METHYLPHENYL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMO-N-(3-METHYLPHENYL)ACETAMIDE(5439-17-8)
• EPA Substance Registry System: 2-BROMO-N-(3-METHYLPHENYL)ACETAMIDE(5439-17-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 5439-17-8(Hazardous Substances Data)

Usage

General Description

2-Bromo-N-(3-methylphenyl)acetamide, also known as N-(3-methylphenyl)-2-bromoacetamide, is a chemical compound with the molecular formula C9H10BrNO. It is a white to off-white crystalline solid that is sparingly soluble in water. 2-Bromo-N-(3-methylphenyl)acetamide is used as an intermediate in the synthesis of pharmaceuticals and other organic compounds. It is also used in the synthesis of benzoxazine derivatives, which have potential applications in the fields of medicine and materials science. Additionally, 2-Bromo-N-(3-methylphenyl)acetamide is a potential irritant, and caution should be exercised when handling it.

InChI:InChI=1/C9H10BrNO/c1-7-3-2-4-8(5-7)11-9(12)6-10/h2-5H,6H2,1H3,(H,11,12)

Upstream product

• 22118-09-8 2-bromoacetyl chloride 
• 108-44-1 1-amino-3-methylbenzene 
• 598-21-0 2-Bromoacetyl bromide 

Downstream Products

• 630118-64-8 2-(4-phenylpiperidin-1-yl)-N-(m-tolyl)acetamide 
• 892424-25-8 2-[{5-(4-nitrophenyl)-1,3,4-oxadiazole-2-yl}sulphanyl]-N-(3-methylphenyl)acetamide 
• 1310459-60-9 2-(3-benzoyl-4-hydroxy-1,1-dioxido-2H-benzo[e][1,2]thiazin-2-yl)-N-(m-tolyl)acetamide 

Relevant articles and documents

Design, synthesis, in vitro antiproliferative evaluation and in silico studies of new VEGFR-2 inhibitors based on 4-piperazinylquinolin-2(1H)-one scaffold

Angiogenesis is essential in the growth of solid tumors which need oxygen and nutrients supply to grow in size. The VEGF/VEGFR-2 signaling pathway plays an important role in tumor angiogenesis. Sorafenib is an FDA approved cancer therapeutic with activity

Synthesis and Antifungal Activity of New N-Aryl-2-(2-hydroxyphenylamino)ethylenediamine Derivatives

Abstract: In this study, a series of new N-aryl-2-(2-hydroxyphenylamino)ethylenediamine derivatives has beendesigned, synthesized and evaluated for antifungal activity against six selectedspecies of phytopathogenic fungi. Among the products, the most potent compoundhave demonstrated 97.7% inhibitory activity against S.sclerotiorum at the concentration of 50 μg/mL, which is higherthan that of the positive control chlorothalonil.

Identification of phenylcarbamoylazinane-1,3,4-oxadiazole amides as lipoxygenase inhibitors with expression analysis and in silico studies

In search for new anti-inflammatory agents that inhibit the enzymes of arachidonic acid pathway as the drug targets, the present article describes the screening of 1,3,4-oxadiazole analogues against lipoxygenase (LOX) enzyme. The work is based on the synthesis of new N-alkyl/aralky/aryl derivatives (6a-o) of 2-(4-phenyl-5-(1-phenylcarbamoylpiperidine)-4H-1,3,4-oxadiazol-3-ylthio)acetamide which were obtained by the reaction of 1,3,4-oxadiazole (3) with various electrophiles (5a-o), in KOH. The synthesized analogues showed potent to moderate inhibitory activity against the soybean 15-LOX enzyme; especially 6g, 6b, 6a and 6l displayed the potent inhibitory potential with IC50 values 7.15 ± 0.26, 9.32 ± 0.42, 15.83 ± 0.45 & 18.37 ± 0.53 μM, respectively, while excellent to moderate inhibitory profiles with IC50 values in the range of 26.13–98.21 μM were observed from the compounds 6k, 6m, 6j, 6o, 6h, 6f, 6n and 6c. Most of the active compounds exhibited considerable cell viability against blood mononuclear cells (MNCs) at 0.25 mM by MTT assay except 6f, 6h, 6k and 6m which showed around 50% cell viability. Flow cytometry studies of the selected compounds 6a, 6j and 6n revealed that these caused 79.5–88.51% early apoptotic changes in MNCs compared with 4.26% for control quercetin at their respective IC50 values. The relative expression of 5-LOX gene was monitored in MNCs after treatment with these three molecules and all down-regulated the enzyme activity. In silico ADME and molecular docking studies further supported these studies of oxadiazole derivatives and considered it as potential ‘lead’ compounds in drug discovery and development.